QRG Capital Management Inc. Buys 50,990 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

QRG Capital Management Inc. boosted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 213.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 74,847 shares of the company's stock after buying an additional 50,990 shares during the period. QRG Capital Management Inc.'s holdings in Genmab A/S were worth $1,465,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC lifted its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares in the last quarter. Barclays PLC lifted its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Cromwell Holdings LLC raised its holdings in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Genmab A/S in the fourth quarter valued at $60,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on GMAB shares. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Wall Street Zen lowered Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Finally, Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Price Performance

GMAB traded down $0.48 on Monday, reaching $20.68. 3,563,028 shares of the company traded hands, compared to its average volume of 1,193,408. The company has a market cap of $13.26 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 6.98 and a beta of 0.96. The stock's 50 day moving average price is $20.92 and its 200-day moving average price is $20.73. Genmab A/S Sponsored ADR has a 52-week low of $17.24 and a 52-week high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. As a group, equities research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.